Tempest Therapeutics (TPST) Stock Price, News & Analysis

Company Overview

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells. Additional preclinical programs aim to block key kinases involved in immune suppression, thereby complementing existing checkpoint inhibitors. Tempest has initiated early‐phase clinical studies in North America and Europe, collaborating with academic and industry partners to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with advanced malignancies.

Founded in 2017 and headquartered in Cambridge, Massachusetts, Tempest Therapeutics was established to translate cutting‐edge metabolic and immunological insights into novel oncology treatments. The company’s leadership team combines expertise in drug discovery, clinical development, and regulatory strategy, with decades of experience at both emerging biotechnology firms and large pharmaceutical companies. Tempest is supported by leading life‐science investors and maintains research collaborations to expand its pipeline and accelerate the delivery of new therapies to patients worldwide.

Key Stats

• Today's Range: $1.05 to $1.12
• 50-Day Range: $1.05 to $2.15
• 52-Week Range: $1.02 to $12.23
• Volume: 81,714 shs
• Average Volume: 150,169 shs
• Market Capitalization: $17.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Tempest Therapeutics Stock Analysis - MarketRank™

Tempest Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 734th out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Tempest Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Tempest Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tempest Therapeutics are expected to grow in the coming year, from ($1.34) to ($1.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tempest Therapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tempest Therapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tempest Therapeutics has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.18% of the float of Tempest Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tempest Therapeutics has a short interest ratio ("days to cover") of 2.04, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tempest Therapeutics has recently decreased by 39.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tempest Therapeutics does not currently pay a dividend.

Dividend Growth

Tempest Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Tempest Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tempest Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

36.30% of the stock of Tempest Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

22.52% of the stock of Tempest Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 7/05/2026
• Next Earnings (Estimated): 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TPST
• CIK: 1544227
• Web: www.millendo.com
• Phone: 415-798-8589
• Fax: N/A
• Employees: 20
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($6.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -355.61%
• Return on Assets: -121.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.74
• Quick Ratio: 0.74

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.35 per share
• Price / Book: 0.81

Miscellaneous

• Outstanding Shares: 15,979,000
• Free Float: 10,179,000
• Market Cap: $17.42 million
• Optionable: No Data
• Beta: -1.73